Skip to main content
Ingredients/Compound/Tetrahydrocannabinol

Tetrahydrocannabinol.

Strength pending.The research strength is not set yet.

THC is the compound in cannabis that produces the high. It partially activates the body's own cannabinoid receptors, and it's legally controlled in most places.

TECompound
TetrahydrocannabinolIngredientMD
Category
Compound

What Tetrahydrocannabinol is, and what it does.

Does it work
This is a controlled compound rather than a general supplement ingredient. Anyone considering it is answering a legal question first and a medical one second.
How much to take
No dose figure is on record. Swallowed THC behaves very differently from inhaled, and clearance varies several fold between people, so any amount is a clinician's call.
Time to feel it
Swallowed, the onset is slow and drawn out, often well over an hour, because the liver converts it first. Inhaled effects arrive within minutes.
The first dose
Day one with an oral amount is unpredictable: a slow build, a longer tail than expected, and often a faster heart rate when you stand up.
With regular use
It's highly fat soluble, so it collects in fat tissue and releases slowly. Metabolites stay detectable on a test for weeks after regular use.
How well tolerated
Dose dependent faster heart rate and blood pressure changes on standing, plus added sedation with other depressants. It's controlled in most places, so check the law where you live.
How it feels
Altered perception, distorted sense of time and sedation, with a wide spread between people. Oral amounts tend to feel stronger and last longer than expected.
The overlooked benefit
Variation in the CYP2C9 enzyme changes clearance several fold, which is why two people taking the same oral amount can have completely different experiences.

The proof, claim by claim.

These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.

  • Appetite stimulationRandomised trial
  • Sleep onset and sleep architectureRandomised trial
  • Short term memory and processing speedMeta-analysis
  • Partial activation of CB1 and CB2 receptorsNarrative review
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.
Pairs well with8 on file

Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.

Tetrahydrocannabinol + CannabidiolCBD is a negative allosteric modulator at CB1 and inhibits several cytochrome P450 enzymes that clear THC.

CBD changes both how THC signals at CB1 and how quickly it is metabolised, which is why the two are almost always discussed as a ratio rather than separately. A systematic review pooled inflammatory biomarker data across studies of both compounds. The direction and size of the modulation depends heavily on dose ratio and route, so the interaction is real but not fixed.

Tetrahydrocannabinol + MCT oilTHC is highly lipophilic with poor water solubility, and medium-chain triglyceride is the standard carrier for oral preparations.

Oral THC absorption is erratic and depends on lipid presence for micellar solubilisation and partial lymphatic transport. A high-fat meal substantially raises systemic exposure from the same oral dose. That variability is why oral onset is slow and unpredictable compared with inhalation.

Tetrahydrocannabinol + Sunflower lecithinPhospholipid emulsification is used to disperse lipophilic cannabinoids in aqueous formats.

Lecithin lets an oil-soluble cannabinoid form a stable dispersion in a water-based product, which is the basis of most nanoemulsion beverages. Better dispersion generally means faster and less variable absorption. This is formulation chemistry, and it does not change what the compound does once absorbed.

Tetrahydrocannabinol + MelatoninBoth act on sleep-related pathways and are frequently combined in night-time products.

THC produces dose-dependent sedation through CB1 signalling while melatonin acts on circadian timing through MT1 and MT2 receptors. Combined, the sedative effect adds, which is worth flagging rather than celebrating. Next-morning impairment is a real consideration, and neither should be combined with driving or operating machinery.

Tetrahydrocannabinol + St John's wortSt John's wort is a potent inducer of CYP3A4 and P-glycoprotein, both involved in THC disposition.

Induction of CYP3A4 speeds clearance of substrates handled by that enzyme, lowering their plasma levels. THC is metabolised by CYP2C9 and CYP3A4, so co-use would be expected to reduce exposure. St John's wort also interacts with a long list of prescription medicines, which is the larger issue in any case.

Tetrahydrocannabinol + Black pepper extract (BioPerine)Piperine inhibits CYP3A4 and P-glycoprotein, the routes that limit oral cannabinoid exposure.

Slowing first-pass metabolism raises plasma levels from the same oral dose. With a compound whose effects are steeply dose-dependent and already variable orally, raising exposure unpredictably is a risk rather than a feature. The inhibition is non-selective and affects co-administered medicines too.

Tetrahydrocannabinol + Omega-3 fish oil (EPA/DHA)An animal study reported that perinatal long-chain omega-3 supplementation offset cognitive deficits linked to prenatal THC exposure.

Endocannabinoids are built from arachidonic acid, and dietary long-chain polyunsaturated fat shifts the membrane precursor pool that feeds that system. The reported offsetting effect was measured in rodents with sex-specific differences. It says nothing about what omega-3 does alongside THC in an adult, and prenatal cannabis exposure is a setting where the only sound advice is avoidance.

Tetrahydrocannabinol + CaffeineOpposing effects on arousal, with caffeine acting through adenosine receptor blockade and THC producing dose-dependent sedation.

Caffeine raises alertness while THC at typical doses lowers it, so the two partly mask each other subjectively. Masking sedation does not restore reaction time or judgement. Both also raise heart rate, and that effect adds rather than cancels.

Who should be cautious

Nothing specific on file for Tetrahydrocannabinol. Match the label to the daily amount above, and tell your doctor what you take.

Not medical advice. Show the label to your pharmacist.

What Tetrahydrocannabinol actually does.

Established

It docks onto the same receptors your own endocannabinoids use, mainly in the brain.

Established

It stores in body fat and leaves slowly, so tests stay positive long after the effect has gone.

Established

Swallowed, it turns into a second active compound in the liver. That is why edibles hit later and harder than people expect.

Established

THC can raise heart rate and cause blood pressure drops on standing in a dose-dependent way through its effects on the nervous system, and it can add to sedation when combined with other depressant substances.

More than one route, 6 steps on record

Where Tetrahydrocannabinol comes from.

The compound in cannabis responsible for the high. Legally controlled in most places, not a general supplement ingredient, and swallowing it is far less predictable than most people assume.

The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.

Starts as
Cannabis sativa flower, or CBD as a chemical starting material

Cannabinoid-rich flower from cultivated plants, or purified CBD used as the substrate for isomerisation routes

Extracted by
CO2, hydrocarbon or ethanol extraction

Cannabinoids are pulled from milled plant material along with waxes, chlorophyll and terpenes

Converted by
Decarboxylation, or acid-catalysed isomerisation

Heat converts THCA to delta-9-THC. Separately, acid catalysis converts CBD to delta-8 or delta-9-THC, which is how most delta-8 material on the market is made

Purified by
Winterisation and distillation

Waxes are dropped at low temperature and the cannabinoid fraction is short-path distilled, with chromatography where an isolate is required

Standardised to
Potency and contaminant testing

Batches are assayed by chromatography for cannabinoid content and screened for residual solvent, pesticide and heavy metal, with requirements set by jurisdiction

Ends up as
Oil, capsule, emulsion or isolate

Formulated into carrier oil, softgels, water-dispersible emulsions, or supplied as crystalline isolate

Whether material is plant-extracted or made by acid conversion from CBD is frequently not stated on retail delta-8 products.

Getting Tetrahydrocannabinol from food.

The whole-food sources on file. A supplement closes the gap, it does not replace dinner.

Hulled hemp seedsHemp seed oilRaw cannabis leaf in a salad

A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.

The forms it comes in.

THC oil or tinctureDecarboxylated delta-9-THC dissolved in a carrier oil, commonly MCT or olive oilFits Regulated medical and adult-use products where measured oral dosing is neededTrade-off Absorption swings widely with meal fat content, and onset is delayed enough that people redose before the first dose lands
Raw cannabinoid acidTetrahydrocannabinolic acid as it exists in the fresh plant, converting to delta-9-THC on heatingFits Raw plant preparations where the acid form is what is presentTrade-off Not psychoactive until decarboxylated, and heat during processing or storage converts it unpredictably
Delta-8 isomerDouble-bond positional isomer of delta-9, usually produced by acid-catalysed conversion of CBD rather than extracted from the plantFits Products in markets where the delta-9 isomer is restrictedTrade-off Semi-synthetic routes leave reaction by-products and residual catalyst, testing standards are inconsistent, and paediatric ingestion cases have been reported
Pharmaceutical synthetic THCSynthetically produced delta-9-THC in sesame oil capsules or oral solution, made to pharmaceutical specificationFits Prescription contexts under medical supervision where identity and content are controlledTrade-off Prescription-only, and the isolated single molecule behaves differently from a whole-plant preparation
Water-dispersible THC emulsionCannabinoid droplets stabilised with emulsifiers such as lecithin for aqueous beveragesFits Drinks and fast-onset formats where oil separation is unacceptableTrade-off Faster onset narrows the window in which someone can judge their dose, and emulsion stability over shelf life varies by manufacturerActive and formulation aid
Whole-plant cannabis extractExtract retaining THC alongside CBD, minor cannabinoids and terpenes at plant-derived ratiosFits Products built around the whole-plant composition rather than an isolateTrade-off Composition varies by cultivar and harvest, which makes reproducible dosing harder than with a defined isolateActive and formulation aid
What the strongest studies found

The essence, in one line each.

  1. Pooled data on cannabidiol and tetrahydrocannabinol described varied effects across inflammatory biomarkers, with heterogeneous study designs limiting the conclusions.Systematic review. Candeloro et al., 2025 (International Journal of Molecular Sciences). PMID 41373770 ↗
  2. Reported ingestions were analysed to characterise the dose of delta-8 tetrahydrocannabinol associated with toxic effects in small children.Case series. Garay et al., 2025 (Injury Epidemiology). PMID 41029884 ↗
  3. A network meta-analysis of bioactive compounds ranked effects on pain intensity and quality of life, naming cannabinoids among the compared interventions.Meta-analysis. Tang et al., 2025 (Frontiers in Pharmacology). PMID 41181607 ↗
  4. Review of pharmacological and nutritional options for altered taste during chemotherapy, in which cannabinoids appear among the strategies described.Systematic review. Mazzoleni et al., 2024 (Clinical Nutrition ESPEN). PMID 38900642 ↗
  5. Perinatal long-chain omega-3 supplementation offset cognitive deficits associated with prenatal THC exposure, with sex-specific differences.Animal study. Lavanco et al., 2026 (European Journal of Pharmacology). PMID 42229740 ↗

These are the studies our verdict leans on, chosen from the 5 we read for Tetrahydrocannabinol. The full linked list is below.

Primary evidence

The studies, linked.

6 sources behind our Tetrahydrocannabinol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.

  1. ClinicalTrials.gov ↗
  2. Clinical trialPharmacogenetics of Cannabinoid Response
    Early phase 1, 72 participants, Completed
    ClinicalTrials.gov ↗
  3. ClinicalTrials.gov ↗
  4. ClinicalTrials.gov ↗
  5. ClinicalTrials.gov ↗
  6. ClinicalTrials.gov ↗

Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.

Side effects reported to the FDA

Problems people have reported.

Read this carefully. These are 6,121 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Tetrahydrocannabinol is, not how risky it is. A report is not proof Tetrahydrocannabinol caused anything. It is a signal of what to watch for, nothing more.

Toxicity To Various Agents
456
Drug Abuse
324
Overdose
197
Vomiting
168
Drug Interaction
161
Anxiety
132

Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.